Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study

<div>Kaplan–Meier curves of progression-free survival (a) and overall survival (b) in patients with advanced non-small-cell lung cancer (NSCLC) and interstitial lung disease treated with carboplatin plus nab-paclitaxel. OS: overall survival; PFS: progression-free survival; PS: performance status; CI: confidence interval.</div>

Canadian Respiratory Journal

fig2

Figure 2

Figure 2: Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study 

Figure 2 | Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study 